 Open access

2,142 Views | 3 CrossRef citations to date | 0 Altmetric

Listen


Author's Views


# USP30: protector of peroxisomes and mitochondria

Victoria Riccio , G. Angus McQuibban & Peter Kijun Kim 

Article: 1600350 | Received 12 Mar 2019, Accepted 25 Mar 2019, Published online: 16 Apr 2019

 Cite this article  <https://doi.org/10.1080/23723556.2019.1600350>

 Check for updates

 Full Article


 Figures & data

 References

 Citations


 Metrics

 Licensing

 Reprints & Permissions

 View PDF

 View EPUB

 Share

## We Care About Your Privacy

We and our 887 partners store and access personal data, like browsing data or unique identifiers, on your device. Selecting I Accept enables tracking technologies to support the purposes shown under we and our partners process data to provide. Selecting Reject All or withdrawing your consent will disable them. If trackers are disabled, some content and ads you see may not be as relevant to you. You can resurface this menu to change your choices or withdraw consent at any time by clicking the Show Purposes link on the bottom of the webpage .Your choices will have effect within our Website. For more details, refer to our Privacy Policy. [Here](#)

We and our partners process data to provide:

Use precise geolocation data. Actively scan device

 I Accept

Reject All

Show Purpose



Mitophagy

Selective autophagy of mitochondria (mitophagy) is a key process in maintaining mitochondrial quality and function. Mitophagy is a selective process that targets damaged or dysfunctional organelles. Even though selective autophagy is necessary for normal

cellular function, and its dysregulation results in many human diseases,<sup>1</sup> surprisingly little is known about how selective autophagy of different substrates is regulated.

Peroxisomes are metabolic organelles responsible for, amongst other things, metabolizing fatty acids and scavenging reactive oxygen species.<sup>2</sup> However, dysregulation in peroxisome homeostasis results in a rare class of genetic disorders, Peroxisome Biogenesis Disorders (PBDs).<sup>3</sup> While the low peroxisome number and function was previously thought to be caused by reduced peroxisome biogenesis, a recent study has shown that the most common form of the disease is caused by increased degradation.<sup>4</sup> Regulation of pexophagy is therefore essential to prevent disease, and thus formed the basis of our study.<sup>5</sup>

Peroxisomes, like mitochondria, are degraded through selective autophagy, termed pexophagy and mitophagy respectively. Pexophagy can be induced by various stimuli, but the focus of our study was amino acid starvation induced pexophagy. Amino acid starvation, through inhibition of mammalian target of rapamycin (mTOR), results in the stabilization of the E3 ligase PEX2 on peroxisome membranes.<sup>6</sup> PEX2 acts to ubiquitinate membrane proteins, resulting in peroxisomal degradation. This serves as the first regulatory step to ensure peroxisomes are not lost under basal conditions.

It has been shown that mitophagy, in addition to the regulation offered by recruitment of the E3 ligase Parkin to damaged organelles, is also negatively regulated by a deubiquitinase.<sup>7</sup> It has previously been shown that the E3 ligase complex describing the role of the E3 ligase complex puncta that did not contain Parkin was ubiquitinated with the E3 ligase complex. This study aimed to characterize the role of the E3 ligase complex in peroxisomal degradation.

We have shown that overexpression of the E3 ligase complex more than the E3 ligase complex (USP30) which is a peroxisome targeting signal, suggesting that USP30 is the next found to be involved in pexophagy upon amino acid starvation. USP34-USP30,




but not TOM20-USP30, was able to demonstrate this inhibition, suggesting that USP30 is acting directly at the peroxisome.

To determine whether USP30 functions to prevent basal pexophagy, we used siRNA mediated knockdown to understand its role under basal conditions. We found that USP30 depletion resulted in increased autophagy dependent peroxisome loss. In addition, co-depletion of PEX2 resulted in an abolishment of the peroxisome loss seen in USP30 depleted cells, suggesting that USP30 acts in opposition to PEX2 and is required to keep basal pexophagy to a minimum. (Figure 1(a))

Figure 1. USP30 regulates basal pexophagy.

a) Under basal conditions, USP30 and PEX2 work in opposition to maintain peroxisome homeostasis. b) During pexophagy induction, USP30 can no longer maintain low peroxisome ubiquitination, autophagy receptors NBR1 and sequestosome 1 (p62) are recruited to facilitate engulfment by the autophagosome and peroxisomes are lost.



Display full

×

As a de  
we want  
showed  
USP30 d  
resulted  
of BR  
regulate

Previous  
in an ac  
peroxiso  
pexopha

. Therefore,  
ng co-IP, we  
ubiquitinated in  
USP30  
tor neighbor  
acts to  
e 1(b))

3D, results  
resulting in  
prevent  
BD cell line

and found that it can rescue the loss of peroxisomes, suggesting a potential therapeutic approach in combatting this disease.

During the revision of our manuscript, a study was published by Sylvie Urbé’s group demonstrating that endogenous USP30 localizes to the peroxisome where it regulates basal pexophagy.<sup>8</sup> Our work adds to their work by the identification of the E3 ligase, and at least two of UPS30’s substrate. Together, these studies demonstrate the novel role of USP30 in pexophagy.

Many questions still remain unanswered. First and foremost, why would the cell have a single regulator for both pexophagy and mitophagy. This gives rise to the question of targeting and regulation. Peroxisomes and mitochondria are degraded under different conditions, one example being amino acid starvation which induces pexophagy while protecting mitochondria.<sup>9</sup> Is there any condition, therefore, that would induce an upregulation of USP30, or a change in its cellular distribution, to allow for degradation of one organelle over the other? We and Urbé’s group have shown that USP30 is targeted to the mitochondria and peroxisome independently. Is this difference in targeting a mechanism by which USP30 differentially regulates these two organelles? Or is USP30 differentially regulated on its target organelle?

Finally, we’ve shown that USP30 is able to increase peroxisomes in PEX1 G843D fibroblasts, suggesting a potential therapeutic approach in disease. While continuing to evaluate USP30’s role in other diseases, we are also investigating its role in other diseases, which are complicated in many types of cells. We are also investigating its role in mitophagy and new therapeutic approaches.



Dis  
No poten

References

1. Anding AL, Baehrecke EH. Developmental cell cleaning house: selective autophagy of organelles. *Dev Cell*. 2017;41:10–22. doi:10.1016/j.devcel.2017.02.016.

 | [PubMed](#) | [Web of Science ®](#) | [Google Scholar](#)

2. Berger J, Dorninger F, Forss-Petter S, Kunze M. Peroxisomes in brain development and function. *Biochim Biophys Acta - Mol Cell Res*. 2016;1863(5):934–955. doi:10.1016/j.bbamcr.2015.12.005.

 | [PubMed](#) | [Web of Science ®](#) | [Google Scholar](#)

3. Braverman NE, D'Agostino MD, MacLean GE. Peroxisome biogenesis disorders: biological, clinical and pathophysiological perspectives. *Dev Disabil Res Rev*. 2013;17(3):187–196. doi:10.1002/ddrr.1113.

 | [PubMed](#) | [Google Scholar](#)

4. Law KB, Bronte-Tinkew D, Di Pietro E, Snowden A, Jones RO, Moser A, Brumell LH, Braverman N, Kim PK. The peroxisomal AAA ATPase complex prevents pexophagy and development of peroxisome biogenesis disorders. *Autophagy* 2017;13(5):868–884. doi:10.1080/15548627.2017.1291470.

 | [PubMed](#) | [Web of Science ®](#) | [Google Scholar](#)

5. Riccio CA, Kim PK, Quibban GA, Kim PK. Peroxisome biogenesis disorders: biological, clinical and pathophysiological perspectives. *Dev Disabil Res Rev*. 2013;17(3):187–196. doi:10.1002/ddrr.1113.

 | [PubMed](#) | [Google Scholar](#)

6. Sargeant JM, Kim PK. Peroxisome biogenesis disorders: biological, clinical and pathophysiological perspectives. *Dev Disabil Res Rev*. 2013;17(3):187–196. doi:10.1002/ddrr.1113.


 | [PubMed](#) | [Google Scholar](#)

7. Wang X, McQuinn M, Kim PK. Peroxisome biogenesis disorders: biological, clinical and pathophysiological perspectives. *Dev Disabil Res Rev*. 2013;17(3):187–196. doi:10.1002/ddrr.1113.

 | [PubMed](#) | [Google Scholar](#)




8. Marcassa E, Kallinos A, Jardine J, Rusilowicz-Jones EV, Martinez A, Kuehl S, Islinger M, Clague MJ, Urbé S. Dual role of USP30 in controlling basal pexophagy and mitophagy. *EMBO Rep.* 2018;19(7):e45595. doi:10.15252/embr.201745595.




[PubMed](#) | [Web of Science ®](#) | [Google Scholar](#)

9. Rambold AS, Kostelecky B, Elia N, Lippincott-Schwartz J. Tubular network formation protects mitochondria from autophagosomal degradation during nutrient starvation. *Proc Natl Acad Sci.* 2011;108(25):10190–10195. doi:10.1073/pnas.1107402108.



[PubMed](#) | [Web of Science ®](#) | [Google Scholar](#)

10. Dahabieh MS, Di Pietro E, Jangal M, Goncalves C, Witcher M, Braverman NE, Del Rincón SV. Peroxisomes and cancer: the role of a metabolic specialist in a disease of aberrant metabolism. *Biochim Biophys Acta - Rev Cancer.* 2018;1870(1):103–121. doi:10.1016/j.bbcan.2018.07.004.



[PubMed](#) | [Web of Science ®](#) | [Google Scholar](#)

[Download PDF](#)

Related



Information for

- Authors
- R&D professionals
- Editors
- Librarians
- Societies

Opportunities

- Reprints and e-prints
- Advertising solutions
- Accelerated publication
- Corporate access solutions

Open access

- Overview
- Open journals
- Open Select
- Dove Medical Press
- F1000Research

Help and information

- Help and contact
- Newsroom
- All journals
- Books

Keep up to date

Register to receive personalised research and resources by email

 Sign me up



Copyright

Accessib

Registered  
5 Howick Pl

or & Francis Group  
orma business

